Paper26316558
Evolving resistance among Gram-positive pathogens.
Munita JM and 2 others. Clin Infect Dis, 2015. Cited by 86 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Evolving resistance among Gram-positive pathogens. Papers, record 26316558. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26316558
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Drug Resistance, Bacterial | Major topic |
| Drug Resistance, Multiple, Bacterial | Major topic |
| Gram-Positive Bacteria | Major topic |
| Gram-Positive Bacterial Infections | Major topic |
| Animals | |
| Evolution, Molecular | |
| Humans | |
| Mutation |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AI039108 | NIAID NIH HHS | United States | R01AI039108 | PubMed and NIH | NIH RePORTER |
| R01 AI093749 | NIAID NIH HHS | United States | R01AI093749 | PubMed and NIH | NIH RePORTER |
| R01 AI39108-15 | NIAID NIH HHS | United States | R01AI391081 | PubMed | NIH RePORTER |
References72
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22,393,892 | Molecular mechanisms of β-lactam resistance in Streptococcus pneumoniae. | Future Microbiol | 2012 | https://conductscience.org/library/papers/22393892 | PubMed |
| 2 | 25,614,044 | Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. | J Antimicrob Chemother | 2015 | https://conductscience.org/library/papers/25614044 | PubMed |
| 3 | 25,000,230 | Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia. | Microb Drug Resist | 2014 | https://conductscience.org/library/papers/25000230 | PubMed |
| 4 | 22,398,650 | Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. | J Antimicrob Chemother | 2012 | https://conductscience.org/library/papers/22398650 | PubMed |
| 5 | 23,478,959 | Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23478959 | PubMed |
| 6 | 17,517,606 | Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17517606 | PubMed |
| 7 | 25,583,724 | Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/25583724 | PubMed |
| 8 | 21,646,483 | Low fitness cost of the multidrug resistance gene cfr. | Antimicrob Agents Chemother | 2011 | https://conductscience.org/library/papers/21646483 | PubMed |
| 9 | 21,690,622 | Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. | Clin Infect Dis | 2011 | https://conductscience.org/library/papers/21690622 | PubMed |
| 10 | 21,899,450 | Genetic basis for in vivo daptomycin resistance in enterococci. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21899450 | PubMed |
| 11 | 22,431,854 | Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. | Clin Infect Dis | 2012 | https://conductscience.org/library/papers/22431854 | PubMed |
| 12 | 25,355,940 | Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. | J Infect Dis | 2015 | https://conductscience.org/library/papers/25355940 | PubMed |
| 13 | 24,092,854 | A current perspective on daptomycin for the clinical microbiologist. | Clin Microbiol Rev | 2013 | https://conductscience.org/library/papers/24092854 | PubMed |
| 14 | 22,664,970 | Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. | Antimicrob Agents Chemother | 2012 | https://conductscience.org/library/papers/22664970 | PubMed |
| 15 | 23,547,139 | Dissecting the mechanisms of linezolid resistance in a Drosophila melanogaster infection model of Staphylococcus aureus. | J Infect Dis | 2013 | https://conductscience.org/library/papers/23547139 | PubMed |
| 16 | 18,257,700 | Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. | Clin Infect Dis | 2008 | https://conductscience.org/library/papers/18257700 | PubMed |
| 17 | 23,896,478 | β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23896478 | PubMed |
| 18 | 19,680,247 | Waves of resistance: Staphylococcus aureus in the antibiotic era. | Nat Rev Microbiol | 2009 | https://conductscience.org/library/papers/19680247 | PubMed |
| 19 | 12,234,875 | Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12234875 | PubMed |
| 20 | 22,421,879 | The rise of the Enterococcus: beyond vancomycin resistance. | Nat Rev Microbiol | 2012 | https://conductscience.org/library/papers/22421879 | PubMed |
Cited by58
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,987,840 | A New Preview of Antibiotic-resistant Spectrum in Community-acquired Pneumonia: A Cross-Sectional Study from Iraq. | Open Respir Med J | 2026 | https://conductscience.org/library/papers/41987840 | PubMed |
| 41,620,502 | Staphylococcus capitis strain producing dual bacteriocins, capidermicin and micrococcin P1, shows broad-spectrum antimicrobial activity. | Sci Rep | 2026 | https://conductscience.org/library/papers/41620502 | PubMed |
| 41,054,619 | LC-MS/MS Method for Simultaneous Quantification of Three Oxazolidinone Antimicrobials in Human Plasma: Application to Therapeutic Drug Monitoring. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41054619 | PubMed |
| 40,787,034 | A Practice Primer and Update on Anti-Bacterial Resistance. | Mo Med | 2025 | https://conductscience.org/library/papers/40787034 | PubMed |
| 40,535,975 | Gram-positive ESKAPE pathogens in Germany: A comprehensive analysis of occurrence and resistance development in animal, food, and environmental sources. | One Health | 2025 | https://conductscience.org/library/papers/40535975 | PubMed |
| 40,529,959 | Adjunctive β-lactams for Staphylococcus aureus bacteremia: a narrative review. | Ther Adv Infect Dis | 2025 | https://conductscience.org/library/papers/40529959 | PubMed |
| 39,878,538 | Transition metal complexes: next-generation photosensitizers for combating Gram-positive bacteria. | Future Med Chem | 2025 | https://conductscience.org/library/papers/39878538 | PubMed |
| 39,766,587 | Evaluation of Antibiotic Resistance Mechanisms in Gram-Positive Bacteria. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39766587 | PubMed |
| 39,726,767 | Unleashing nature's defense: potent antimicrobial power of plant extracts against oral pathogens and Streptococcus mutans biofilms. | Front Oral Health | 2024 | https://conductscience.org/library/papers/39726767 | PubMed |
| 39,682,751 | Perspectives on Microbiome Therapeutics in Infectious Diseases: A Comprehensive Approach Beyond Immunology and Microbiology. | Cells | 2024 | https://conductscience.org/library/papers/39682751 | PubMed |
| 39,464,831 | Drug Repurposing: Research Progress of Niclosamide and Its Derivatives on Antibacterial Activity. | Infect Drug Resist | 2024 | https://conductscience.org/library/papers/39464831 | PubMed |
| 39,274,926 | Investigation on the Synergy between Membrane Permeabilizing Amphiphilic α-Hydrazido Acids and Commonly Used Antibiotics against Drug-Resistant Bacteria. | Molecules | 2024 | https://conductscience.org/library/papers/39274926 | PubMed |
| 39,015,246 | Antibiogram of Bacteria Isolated from Bloodstream Infection-Suspected Patients at the University of Gondar Comprehensive Specialized Hospital in Northwest Ethiopia: A Retrospective Study. | Int J Microbiol | 2024 | https://conductscience.org/library/papers/39015246 | PubMed |
| 38,951,840 | Analysis of molecular epidemiological characteristics and antimicrobial susceptibility of vancomycin-resistant and linezolid-resistant Enterococcus in China. | BMC Med Genomics | 2024 | https://conductscience.org/library/papers/38951840 | PubMed |
| 38,920,588 | D-Glucose-Mediated Gold Nanoparticle Fabrication for Colorimetric Detection of Foodborne Pathogens. | Biosensors (Basel) | 2024 | https://conductscience.org/library/papers/38920588 | PubMed |
| 38,792,231 | Modeling of Effectiveness of N3-Substituted Amidrazone Derivatives as Potential Agents against Gram-Positive Bacteria. | Molecules | 2024 | https://conductscience.org/library/papers/38792231 | PubMed |
| 38,276,161 | Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician? | Pathogens | 2024 | https://conductscience.org/library/papers/38276161 | PubMed |
| 38,275,314 | Progressive Design of a Ranatuerin-2 Peptide from Amolops wuyiensis: Enhancement of Bioactivity and In Vivo Efficacy. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/38275314 | PubMed |
| 36,995,227 | Top-Down Genomic Surveillance Approach To Investigate the Genomic Epidemiology and Antibiotic Resistance Patterns of Enterococcus faecium Detected in Cancer Patients in Arkansas. | Microbiol Spectr | 2023 | https://conductscience.org/library/papers/36995227 | PubMed |
| 36,742,328 | IgY antibodies: The promising potential to overcome antibiotic resistance. | Front Immunol | 2023 | https://conductscience.org/library/papers/36742328 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26316558
GET https://conductscience.org/api/papers/v1/26316558/references?page=2